Across TCGA pan-cancer cohorts, SLC35G2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of SLC35G2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC35G2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC35G2 is over-expressed in tumor.
CCRCC are the cancer types where SLC35G2 tumor–normal differential expression is most reproducible.